Jade Biosciences Appoints Brad Dahms as Chief Financial Officer Amid Strategic Growth Initiatives

Reuters
07-01
<a href="https://laohu8.com/S/JBIO">Jade Biosciences</a> Appoints Brad Dahms as Chief Financial Officer Amid Strategic Growth Initiatives

Jade Biosciences Inc., a biotechnology company focused on therapies for autoimmune diseases, has appointed Brad Dahms as its new Chief Financial Officer. Dahms brings extensive experience in corporate strategy, business development, and capital markets, having previously held CFO positions at IDRx and Theseus Pharmaceuticals. His appointment follows Jade Biosciences' recent Nasdaq listing and private financing, as the company advances its lead candidate JADE101 into clinical trials for IgA nephropathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9487123-en) on July 01, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10